Visit Site

Epioxa is Now FDA Approved

Corneal Health Solutions

Get There in Time

We’re transforming the standard of care for patients with progressive keratoconus and other corneal ectatic conditions through our commitment to addressing important unmet clinical needs in corneal health.

With inspired innovation, a customer-centric focus, and prolific market access capabilities, we are in the constant pursuit of developing proven solutions in corneal health that empower eye care professionals to deliver optimal care for patients

Contact Sales Rep

Corneal Health Therapies

iLink® Corneal Cross-Linking

iLink® is the only FDA-approved corneal cross-linking procedure proven safe & effective to slow or halt progressive keratoconus.

View Therapy

What are the signs and symptoms of progressive keratoconus, and how can corneal cross-linking help?

Learn More

Resources for Your Practice

Our Comprehensive Support.
Your Uncompromising Patient Care.

Integrating iLink® into your practice helps you expand care, and provide a wider range of benefits to many of your patients. As a trusted industry leader, we have the experience, tools, and training to make integration easy.

Physician
Resources

Highly-personalized
practice resources.

View Resources

Clinical
Data

Outcomes for trials conducted on
the iLink® procedure

View Clinical Data

Market Access Support

Looking for
Insurance
Reimbursement
Information?

Every patient deserves access to procedures that can help preserve their vision. iLink® corneal cross-linking helps patients avoid sight-threatening disease progression. That’s why GPS (Glaukos Patient Services) provides strategic and trustworthy market access solutions for all Glaukos procedures and products in glaucoma, corneal health, and retinal disease care.

Learn More

Explore Patient Resources for Keratoconus Treatment Options

View Patient Website

Contact Us Today
to Integrate the iLink®
Procedure Into Your
Practice

Explore additional information about iLink® in our digital brochure and learn how the procedure is transforming the standard of care for progressive keratoconus.

Request
More Info

"*" indicates required fields

Address*
Glaukos will use the information you provide on this form to be in touch with you.*
This field is for validation purposes and should be left unchanged.

IMPORTANT SAFETY INFORMATION

The most common side effects were red eye, haze, sensitivity to light, disruption of surface cells of the cornea, eye pain, eye irritation, watery eyes, swelling of eyelid, fine white lines in the cornea, reduced sharpness of vision, dry eye, and eye inflammation.

You should not have the EPIOXA™ corneal collagen cross-linking procedure if you have a known hypersensitivity to any ingredients in the product, have had cataract surgery and either did not receive an artificial lens in your eye or received a non-UV blocking artificial lens, have a history of herpetic keratitis, or are pregnant.

If you have any additional questions, please contact your doctor. Please see full Prescribing Information for EPIOXA HD and EPIOXA.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also call Glaukos at 1-888-404-1644.

APPROVED USES

The EPIOXA corneal collagen cross-linking procedure is performed by your eye doctor for the treatment of keratoconus. It does not require the removal of the corneal epithelium (outermost layer of the front of the eye). It consists of EPIOXA™ HD (riboflavin 5′-phosphate ophthalmic solution) 0.239% and EPIOXA™ (riboflavin 5′-phosphate ophthalmic solution) 0.177%, which are prescription eye drops used in combination with the O2n™ System and Boost Goggles®.

The EPIOXA corneal collagen cross-linking procedure is for the treatment of keratoconus in adults and pediatric patients 13 years of age and older.

Please Select Your Country

Continue